COVID-19 Monoclonal Antibody Therapeutics Information for Providers
Casirivimab/imdevimab, bamlanivimab/etesevimab, and sotromivab were granted emergency use authorization for the treatment of mild to moderate COVID-19. Until the national supply of these monoclonal antibodies (mAbs) is sufficient, the Iowa Department of Public Health and the United States government will help facilitate allocation across Iowa.
Find a COVID-19 Monoclonal Antibody Provider
HHS mAb Site Locator NICA mAb Site Locator
Request COVID-19 Monoclonal Antibodies
Casirivimab/imdevimab, bamlanivimab/etesevimab and sotromivab are available at no cost to providers. Providers can submit a request to receive monoclonal antibodies here. By submitting a request, sites are required to:
- Provide AmerisourceBergen with board of pharmacy license or physician letter of authorization
- Attest to their designated class of trade and that they will administer authorized product according to the EUA
- Provide utilization data via Teletracking or NHSN
Additional information on the distribution process can be found here.
Bamlanivimab/Etesevimab (Eli Lilly)